Skip to main content
Team

Discovering next-generation treatments for the mind and body

Menu

Cellics’s management team, board of directors and scientific advisory boards are industry leaders with extensive experience in bringing new pharmaceuticals from discovery to market. This experience with drug development and clinical practice and research allows Cellics to rapidly advance a pipeline of proprietary, optimized and scalable mental health and pain management medicines.

Joseph Tucker, Ph.D.

Chief Executive Officer, Director

Avani Kanubaddi

President & COO

Bob Dagher, M.D.

Chief Medical Officer

Peter Facchini, Ph.D.

Chief Innovation Officer

Carter Ward

Chief Financial Officer

David Johnson

Executive Chairman

George Kegler

Director and Chair of the Audit Committee

Douglas Lind, M.D.

Director

Sol Mayer

Director

Marcus Schabacker, M.D., Ph.D.

Director

Joseph Tucker, Ph.D.

Chief Executive Officer, Director

Michael J. Zelefsky, M.D.

Chairman

Vice Chair, Department of Radiation Oncology, Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center
Specialization in Clinical Research

Angus Dalgleish, M.D.

Professor, St. George’s University of London
Specialization in Oncology Research

James Perry, M.D.

Neuro-Oncologist, Sunnybrook Research Institute
Professor, University of Toronto
Specialization in Clinical Research

Zvi Vogel, Ph.D.

Professor, Neurobiology, Weizmann Institute
Specialization in Oncology Research, Patent Contributor

Dallas Hack, M.D., M.P.H.

Brain health expert and board certified in Preventive Medicine
Coordinated $2B+ in Medical Research at the US Army Medical Research & Material Command

A Revolutionary Approach to Treatment

Cellics’ dynamic platform technology leverages the power of cell membranes to craft specialized nanoparticles. Derived from a variety of wild type or engineered human cells, the Cellular Nanoparticles (CNP™) Technology has the potential to improve therapeutic efficacy and safety for many complex diseases.